Leadership Team | Scientific Advisory Board | Board of Directors

Toragen Team

Dr. Sandra Coufal, MD

Dr. Sandra Coufal, MD

CEO

Dr. Andrew Sharabi, MD/PhD

Dr. Andrew Sharabi, MD/PhD

Founder

Anita Busquets

Anita Busquets

CFO

Richard Lumpkin, PhD

Richard Lumpkin, PhD

Director of R & D

John Reiner

John Reiner, PhD

Chemist/SAR Lead

James Kanter

James Kanter, PhD

CMC expert

Elizabeth Vadas

Elizabeth Vadas, PhD

Formulation Expert

Roger Dilts

Roger Dilts, PhD

Drug Development

Jeff Hartlin

Jeff Hartlin

Outside Counsel

Dr. Harry Gruber, MD

Dr. Harry Gruber, MD

Chair of SAB and Senior Advisor to CEO

Dr. Ezra Cohen, MD

Dr. Ezra Cohen, MD

Scientific Advisor

Dr. Dennis Carson, MD

Dr. Dennis Carson, MD

Scientific Advisor

John Major

John Major

Board Member

Kimberly Manhard

Kimberly Manhard

Board Member

Daniel Solorio

Daniel Solorio

Regulatory Ops

Faye Hunter

Faye Hunter

Licensing

Leadership Team

Dr. Sandra Coufal, MD

Dr. Sandra Coufal, MD

CEO

Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology.

  • Co-founded and managed Sibling Capital Ventures and Sibling Capital
  • Founded Relypsa’s and Ilypsa’s Scientific Advisory Boards
  • Co-founded and serves as Director on the Management Board of Tricida, Inc. (NASDAQ: TCDA)

Dr. Coufal received her medical degree from the University of Texas Southwestern Medical School at Dallas. Previously, Dr. Coufal was Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic in La Jolla, CA, where she also sat on the Board of Scripps Green Hospital as the Representative-at-Large. She also completed an internship and residency in Internal Medicine at the University of Texas Southwestern Medical School at Dallas under Chairman Dr. Daniel Foster. She received her Bachelor of Science undergraduate degree from the University of Notre Dame and was designated a Notre Dame Scholar.

Dr. Andrew Sharabi, MD/PhD

Dr. Andrew Sharabi, MD/PhD

Founder

Dr. Andrew Sharabi is a Board Certified Radiation Oncologist and Associate Professor at UC San Diego, and physician-scientist with a PhD in Immunology who specializes in treating Head and Neck Cancer.

  • Internationally Recognized expert on Radiation and Immunotherapy
  • Principle investigator of Phase I and Phase II clinical trials
  • Director of Radiation Medicine Core Facility at Moores Cancer Center
  • Scientific Advisor for San Diego Center for Precision Immunotherapy

Dr. Sharabi worked at Johns Hopkins University in the Immunology Research Program Under Drs. Charles Drake and Drew Pardoll who helped to discover the PD-1 checkpoint pathway.

Anita Busquets

Anita Busquets

CFO

Ms. Anita Busquets is a highly experienced startup executive who has served as President, CFO, COO, and Director of multiple companies including:

  • Chief Financial Officer and Director of KI Investment Holdings
  • Chief Financial and Administrative Officer of Salmedix Inc.
  • Co-founded and served as the President and COO at GeneTex, Inc.
  • Director of Finance and Administration for Corvas International
  • President and Chief Operating Officer of NCE Pharmaceuticals, Inc.
  • Chief Operating Officer at the CTRC Research Foundation, where she was instrumental in incubating and spinning out Ilex Oncology

Ms. Busquets holds an M.B.A. from Simmons College Graduate School of Management and a B.S. from Cornell University.

Richard Lumpkin, PhD

Richard Lumpkin, PhD

Director of Research and Development

Dr. Richard Lumpkin has over 30 years of experience in early stage biotechnology companies and synthetic chemistry. He previously served as Senior Director at Global Blood Therapeutics becoming the first employee of this Third Rock Ventures founded company. He also played an instrumental part in spinning off Portola Pharmaceuticals from Millennium Pharmaceuticals. He held positions as a synthetic chemist and computer programmer at COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.

Dr. Lumpkin received his undergraduate and graduate degrees in Biochemistry from the University of Missouri – Columbia.

Jeff Hartlin

Jeff Hartlin

Outside Counsel

Mr. Jeff Hartlin is partner and chair of the Corporate practice of Paul Hastings and is based in the firm’s Palo Alto and San Diego offices. He concentrates his practice in corporate law, capital-raising, mergers & acquisitions and securities and has represented several public and private companies in equity and debt private placements with a combined value of several billion. He also routinely represents startup and other early-stage companies from incorporation through early financing, pre-IPO capital raising, IPO and eventual sale.

Mr. Hartlin received his B.A. from University of California Davis and J.D. from University of Virginia School of Law.

Faye Hunter

Faye Hunter

Technology Licensing Consultant and Investor

Ms. Faye Hunter is a retired partner at Latham & Watkins LLP. She focused her practice on the representation of emerging growth companies, ranging from startup venture-backed to mature public companies. She also served on the Board of Trustees for Salk Institute and San Diego Public Library. Ms. Hunter has expertise in corporate governance issues and frequently advises boards of directors and management on these issues. She also has assisted companies in developing and executing acquisition and licensing strategies, whether in connection with the initial in-licensing of technology or complex corporate alliance or partnering transactions.

Ms. Hunter received her AB from Stanford University and JD from the University of San Diego School of Law.

Scientific Advisory Board

Dr. Harry Gruber, MD

Dr. Harry Gruber, MD

As one of the first pioneers in gene therapy, Dr. Gruber has been the co-founder and/or inventor of the underlying technology for the following public companies, which achieved a combined value over $7 billion: Gensia Pharmaceuticals, Inc. (ultimately acquired by Teva Pharmaceutical Industries, Ltd.), Viagene, Inc. (a gene therapy company ultimately acquired by Novartis Pharmaceuticals), Aramed, Inc. (ultimately acquired by Gensia Pharmaceuticals, Inc.), Metabasis, Inc., INTERVU Inc. (ultimately acquired by Akamai Technologies, Inc.) and Kintera, Inc. He is the author of over 100 original scientific articles and an inventor on over 33 issued and numerous pending patents. Dr. Gruber holds a BA and a MD from the University of Pennsylvania and trained in Internal Medicine, Biochemical Genetics and Rheumatology/Immunology at the University of California, San Diego.

Dr. Ezra Cohen, MD

Dr. Ezra Cohen, MD

Dr. Ezra Cohen is a Professor of Medicine UC San Diego and the Associate Director, Translational Science, at the UCSD Moores Cancer Center. He is a Co-director of the San Diego Center for Precision Immunotherapy and is a prior chair of the NCI Steering Committee for Head and Neck Cancer.

Dr. Dennis Carson, MD

Dr. Dennis Carson, MD

Dr. Dennis Carson is a Professor of Medicine at UC San Diego. He is the prior Director of the UCSD Moores Cancer Center. National Academy of Sciences and the National Institute of Medicine.

Board of Directors

Dr. Sandra Coufal, MD

Dr. Sandra Coufal, MD

Dr. Andrew Sharabi, MD/PhD

Dr. Andrew Sharabi, MD/PhD

John Major

John Major

Kimberly Manhard

Kimberly Manhard

Anita Busquets

Anita Busquets

%d bloggers like this: